There are gifts, and then there are gifts, the ones inventive enough to surprise and delight the recipient. Some are fun; ...
Medpage Today on MSN
WIC Telehealth Program Improved Diet, Had Modest Impact on Weight Gain in Pregnancy
Recommendations for optimal gestational weight gain are different depending on a woman's body mass index (BMI), ranging from ...
The MarketWatch News Department was not involved in the creation of this content.-- Third quarter 2025 revenue of $9.5 million, up 10% year-over-year -- Amended credit agreement w ...
Trailing Twelve-Month Core Product Sales -- $37 million, a company record, up from $33.8 million, with distributor and ...
Q3 2025 Earnings Call Transcript November 13, 2025 BioHarvest Sciences Inc. Common Stock reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14. Operator: ...
Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsPhillip Chan - CEO & DirectorPeter Mariani ...
In July/August, the Company completed a mechanical stripping and sampling program near the collar of hole MC25-180 to expose ...
Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026New preclinical data demonstrated SIL204’s ...
Net Loss: $3.24 million attributable to Cycurion for the third quarter 2025 ($1.59 loss per basic share); $18.78 million for the nine months ended September 30, 2025 ($14.82 loss per basic share), ...
Q1 2026 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsNicole JosephLeeAnn Rohmann - CEO, Chairman ...
Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone amylin that slows digestion and reduces hunger.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback